Emerging B-Cell Therapies in Systemic Lupus Erythematosus

Ayse Bag-Ozbek,1 Joyce S Hui-Yuen2– 4 1Division of Rheumatology, Renaissance School of Medicine, Stony Brook University Medical Center, Stony Brook, NY, USA; 2Division of Pediatric Rheumatology, Steven and Alexandra Cohen Children Medical Center, New Hyde Park, NY, USA; 3Zucker School of M...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Bag-Ozbek A, Hui-Yuen JS
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	systemic lupus erythematosus treatment novel b cell therapies belimumab rituximab epratuzumab Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/0f39e0e280bd46ca8abcec20e52204ff
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0f39e0e280bd46ca8abcec20e52204ff
record_format	dspace
spelling	oai:doaj.org-article:0f39e0e280bd46ca8abcec20e52204ff2021-12-02T13:52:04ZEmerging B-Cell Therapies in Systemic Lupus Erythematosus1178-203Xhttps://doaj.org/article/0f39e0e280bd46ca8abcec20e52204ff2021-01-01T00:00:00Zhttps://www.dovepress.com/emerging-b-cell-therapies-in-systemic-lupus-erythematosus-peer-reviewed-article-TCRMhttps://doaj.org/toc/1178-203XAyse Bag-Ozbek,1 Joyce S Hui-Yuen2– 4 1Division of Rheumatology, Renaissance School of Medicine, Stony Brook University Medical Center, Stony Brook, NY, USA; 2Division of Pediatric Rheumatology, Steven and Alexandra Cohen Children Medical Center, New Hyde Park, NY, USA; 3Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA; 4Center for Autoimmune, Musculoskeletal, and Hematopoietic Diseases Research, Feinstein Institute for Medical Research, Manhasset, NY, USACorrespondence: Joyce S Hui-YuenDivision of Pediatric Rheumatology, Steven and Alexandra Cohen Children Medical Center, 1991 Marcus Avenue, Suite M100, New Hyde Park, NY 11040, USATel +1 516.472.3700Fax +1 516.472.3752Email jhuiyuen@nshs.eduAbstract: Systemic lupus erythematosus (SLE) is a chronic, multisystem, autoimmune disease of unknown etiology, whose hallmark is the production of autoantibodies. B cells are promising targets for novel SLE therapies. In 2011, belimumab (Benlysta®), a fully humanized monoclonal antibody inhibiting B-cell activation and proliferation, was the first medication in 50 years to be approved by the US Food and Drug Administration to treat adult SLE. This review discusses the current experience with B-cell-targeted therapies, including those targeting B-cell-surface antigens (rituximab, ocrelizumab, ofatumumab, obinutuzumab, obexelimab, epratuzumab, daratumumab), B-cell survival factors (belimumab, tabalumab, atacicept, blisibimod), or B-cell intracellular functions (ibrutinib, fenebrutinib, proteasome inhibitors), for the management of SLE. It focuses on ongoing clinical trials and real-world post-marketing use, where available, including their safety profiles, and concludes with our recommendations for B-cell-centric approaches to the management of SLE.Keywords: systemic lupus erythematosus, treatment, novel B-cell therapies, belimumab, rituximab, epratuzumabBag-Ozbek AHui-Yuen JSDove Medical Pressarticlesystemic lupus erythematosustreatmentnovel b cell therapiesbelimumabrituximabepratuzumabTherapeutics. PharmacologyRM1-950ENTherapeutics and Clinical Risk Management, Vol Volume 17, Pp 39-54 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	systemic lupus erythematosus treatment novel b cell therapies belimumab rituximab epratuzumab Therapeutics. Pharmacology RM1-950
spellingShingle	systemic lupus erythematosus treatment novel b cell therapies belimumab rituximab epratuzumab Therapeutics. Pharmacology RM1-950 Bag-Ozbek A Hui-Yuen JS Emerging B-Cell Therapies in Systemic Lupus Erythematosus
description	Ayse Bag-Ozbek,1 Joyce S Hui-Yuen2– 4 1Division of Rheumatology, Renaissance School of Medicine, Stony Brook University Medical Center, Stony Brook, NY, USA; 2Division of Pediatric Rheumatology, Steven and Alexandra Cohen Children Medical Center, New Hyde Park, NY, USA; 3Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA; 4Center for Autoimmune, Musculoskeletal, and Hematopoietic Diseases Research, Feinstein Institute for Medical Research, Manhasset, NY, USACorrespondence: Joyce S Hui-YuenDivision of Pediatric Rheumatology, Steven and Alexandra Cohen Children Medical Center, 1991 Marcus Avenue, Suite M100, New Hyde Park, NY 11040, USATel +1 516.472.3700Fax +1 516.472.3752Email jhuiyuen@nshs.eduAbstract: Systemic lupus erythematosus (SLE) is a chronic, multisystem, autoimmune disease of unknown etiology, whose hallmark is the production of autoantibodies. B cells are promising targets for novel SLE therapies. In 2011, belimumab (Benlysta®), a fully humanized monoclonal antibody inhibiting B-cell activation and proliferation, was the first medication in 50 years to be approved by the US Food and Drug Administration to treat adult SLE. This review discusses the current experience with B-cell-targeted therapies, including those targeting B-cell-surface antigens (rituximab, ocrelizumab, ofatumumab, obinutuzumab, obexelimab, epratuzumab, daratumumab), B-cell survival factors (belimumab, tabalumab, atacicept, blisibimod), or B-cell intracellular functions (ibrutinib, fenebrutinib, proteasome inhibitors), for the management of SLE. It focuses on ongoing clinical trials and real-world post-marketing use, where available, including their safety profiles, and concludes with our recommendations for B-cell-centric approaches to the management of SLE.Keywords: systemic lupus erythematosus, treatment, novel B-cell therapies, belimumab, rituximab, epratuzumab
format	article
author	Bag-Ozbek A Hui-Yuen JS
author_facet	Bag-Ozbek A Hui-Yuen JS
author_sort	Bag-Ozbek A
title	Emerging B-Cell Therapies in Systemic Lupus Erythematosus
title_short	Emerging B-Cell Therapies in Systemic Lupus Erythematosus
title_full	Emerging B-Cell Therapies in Systemic Lupus Erythematosus
title_fullStr	Emerging B-Cell Therapies in Systemic Lupus Erythematosus
title_full_unstemmed	Emerging B-Cell Therapies in Systemic Lupus Erythematosus
title_sort	emerging b-cell therapies in systemic lupus erythematosus
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/0f39e0e280bd46ca8abcec20e52204ff
work_keys_str_mv	AT bagozbeka emergingbcelltherapiesinsystemiclupuserythematosus AT huiyuenjs emergingbcelltherapiesinsystemiclupuserythematosus
_version_	1718392362257874944

Emerging B-Cell Therapies in Systemic Lupus Erythematosus

Ejemplares similares